Considering the crucial role of PPARα in myocardial energy production, it is reasonable to hypothesize that the beneficial effects of SGLT2 inhibitors on HF patients may be mediated through the regulation of the PPARα signaling pathway to enhance cardiac energy supply, thereby improving HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.